General

Roots Analysis has announced the addition of “Bacteriophage Therapeutics Market, 2022-2035” report to its list of offerings.   Key Market Insights Over 100 bacteriophage therapeutics have either been marketed / are being developed by various well-established and small firms; majority of these therapeutics are being evaluated for the treatment of infectious diseases Around 50% of the pipeline candidates are currently under clinical phase of development; of these, close to 50% are designed for oral and topical administration Multiple clinical studies, evaluating various types of bacteriophage therapeutics among more than 3,000 patients across different centers / hospitals, have been registered worldwide Over the years, the intellectual capital related to bacteriophage therapeutics has grown at a significant pace, with several patents being filed by both industry and non-industry players A notable increase in published scientific literature related to bacterio-phage therapeutics has been observed over the years, demonstrating the growing interest in this domain Various organizations have extended financial support to aid the ongoing research for bacteriophage therapies; currently, the focus, in terms of funds disbursed, is on clinical investigation of bacteriophage therapeutics Several investors, having realized the benefits and future opportunity, have invested over USD 1 billion since 2017 The rising interest of stakeholders is also reflected by the number of partnerships signed in the recent past, involving players located in different geographical regions Our proprietary start-up health indexing analysis confirms the presence of several new entrants that claim to possess the required capabilities for developing bacteriophage therapeutics The bacteriophage market is anticipated to grow at a CAGR of ~10% till 2035; the forecasted opportunity is likely to be distributed across different therapeutic areas, routes of administration, and geographical regions   Table of Content 1.                     PREFACE 1.1.                  Scope of the Report 1.2.                  Market Segmentations 1.3.                  Research Methodology 1.4.                  Key Questions Answered 1.5.                  Chapter Outlines   2.                     EXECUTIVE SUMMARY   3.                     INTRODUCTION 3.1.                  Chapter Overview 3.2.                  Historical Evolution of Bacteriophages 3.3.                  Biology of Bacteriophages 3.4.                  Introduction to Bacteriophage Therapy 3.5.                  Applications of Bacteriophage Therapy 3.6.                  Advantages of Bacteriophage Therapy 3.7.                  Limitations of Bacteriophage Therapy 3.8.                  Conclusion   4.                     BACTERIOPHAGE THERAPEUTICS: MARKET LANDSCAPE 4.1.                  Chapter Overview 4.2.                  Bacteriophage Therapeutics: Drug Pipeline 4.2.1.               Analysis by Phase of Development 4.2.2.               Analysis by Therapeutic Area 4.2.3.               Analysis by Phase of Development and Therapeutic Area 4.2.4.               Analysis by Targeted Bacterial Strain 4.2.5.               Analysis by Target Disease Indication 4.2.6.               Analysis by Type of Therapy 4.2.7.               Analysis by Route of Administration   4.3.                  Information on Bacteriophage Related Technologies   5.                     BACTERIOPHAGE THERAPEUTICS: DEVELOPER LANDSCAPE 5.1.                  Chapter Overview 5.2.                  Bacteriophage Therapeutics: List of Developers 5.2.1.               Analysis by Year of Establishment 5.2.2.               Analysis by Company Size 5.2.3.               Analysis by Location of Headquarters 5.2.4.               Analysis by Company Size and Location of Headquarters 5.2.5.               Leading Developers: Analysis by Number of Bacteriophage Therapeutics   6.                     COMPANY AND DRUG PROFILES 6.1.                  Chapter Overview 6.2.                  Eliava BioPreparations 6.3.                  Micreos 6.4.                  NPO Microgen 6.5.                  ContraFect 6.6.                  Adaptive Phage Therapeutics 6.7.                  Phagelux 6.8.                  Pherecydes Pharma   7.                     CLINICAL TRIAL ANALYSIS 7.1.                  Chapter Overview 7.2.                  Scope and Methodology   7.3.                  Bacteriophage Therapeutics Market: Clinical Trial Analysis   8.                     PATENT ANALYSIS 8.1.                  Chapter Overview 8.2.                  Scope and Methodology   8.3.                  Bacteriophage Therapeutics: Patent Analysis   8.4.                  Bacteriophage Therapeutics: Patent Benchmarking 8.5.                  Bacteriophage Therapeutics: Patent Valuation 8.6.                  List of Leading Patents   9.                     PUBLICATION BENCHMARKING ANALYSIS 9.1.                  Chapter Overview 9.2.                  Scope and Methodology 9.3.                  Publication Benchmarking   10.                   ACADEMIC GRANTS ANALYSIS 10.1.                Chapter Overview 10.2.                Scope and Methodology   10.3.                Bacteriophage Therapeutics: Academic Grant Analysis   11.                   FUNDING AND INVESTMENT ANALYSIS 11.1.                Chapter Overview 11.2.                Types of Funding 11.3.                Bacteriophage Therapeutics Market: List of Funding and Investments 11.4.                Concluding Remarks   12.                   PARTNERSHIPS AND COLLABORATIONS 12.1.                Chapter Overview 12.2.                Partnership Models 12.3.                Bacteriophage Therapeutics: List of Partnerships and Collaborations   13.                   START-UP HEALTH INDEXING 13.1.                Chapter Overview 13.2.                Bacteriophage Therapeutics Developers: Start-ups 13.3.                Benchmarking of Start-ups   14.                   MARKET FORECAST AND OPPORTUNITY ANALYSIS 14.1.                Chapter Overview 14.2.                Scope and Assumptions 14.3.                Forecast Methodology 14.4.                Global Bacteriophage Therapeutics Market, 2022-2035   15.                   CONCLUSION   16.                   EXECUTIVE INSIGHTS 16.1.                Chapter Overview 16.2.                Rime Bioinformatics 16.2.1.             Company Snapshot 16.2.2.             Interview Transcript: Antoine Culot, Chief Executive Officer   16.3.                BiomX 16.4.                Hospices Civils De Lyon 16.5.                Independent Consultant             17.                   APPENDIX I: TABULATED DATA   18.                   APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS   For additional details, please visit https://www.rootsanalysis.com/reports/bacteriophage-therapy-market.html   You may also be interested in the following titles: Nanoparticle Formulation Market mRNA Therapeutics and mRNA Vaccines Industry: Current Scenario and Future Trends Cell Therapy Manufacturing Market Roots Analysis Consulting - the preferred research partner for global firms   About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.   Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com    

Roots Analysis has done a detailed study on Deep Learning in Drug Discovery and Deep Learning in Diagnostics Market, covering important aspects of the industry and identifying key future growth opportunities.   Key Market Insights Presently, more than 70 players across the globe claim to offer deep learning technologies for potential applications across various steps of drug discovery and development process Majority (70%) of the stakeholders employ proprietary deep learning-based technologies in drug discovery to offer big data analysis  Nearly 50% of the deep learning-based diagnostic providers are based in North America; most such players offer technologies for use across medical imaging and medical diagnosis related applications Around 70% of the players engaged in offering deep learning solutions for diagnostics have been established post-2011; majority of the players offer solutions focused on oncological disorders Foreseeing the lucrative potential, a large number of players have made investments worth over USD 15 billion, across 210 funding instances, to advance the initiatives undertaken by industry stakeholders Over the past few years, more than 704,000 patients have been recruited / enrolled in clinical trials registered for deep learning-based solutions / diagnostics across different geographies Our proprietary benchmarking analysis, based on a variety of parameters, indicates the leading start-ups / small firms that are spearheading innovation in this domain    Some players have managed to establish strong competitive positions; in the near future, we expect multiple acquisitions to take place wherein the relative valuation of a firm is likely to be a key determinant Increasing adoption of deep learning technologies in the life sciences and healthcare industry is anticipated to create profitable business opportunities for the technology developers The market opportunity associated with deep learning in drug discovery is expected to witness an annualized growth rate of 23% over the coming 12 years In the long term, the opportunity for deep learning in diagnostics is projected to grow exponentially; the market is likely to be well distributed across various therapeutic areas and geographical regions   Table of Contents   1.                PREFACE 1.1.             Introduction 1.2.             Key Market Insights 1.3.             Scope of the Report 1.4.             Research Methodology 1.5.             Frequently Asked Questions 1.6.             Chapter Outlines   2.                EXECUTIVE SUMMARY   3.                INTRODUCTION 3.1.             Humans, Machines and Intelligence 3.2.             The Science of Learning 3.3.             The Big Data Revolution 3.4.             Deep Learning in Healthcare 3.5.             Concluding Remarks   4.                MARKET OVERVIEW: DEEP LEARNING IN DRUG DISCOVERY 4.1.             Chapter Overview 4.2.             Deep Learning in Drug Discovery: Overall Market Landscape of Service / Technology Providers   5.                MARKET OVERVIEW: DEEP LEARNING IN DIAGNOSTICS 5.1.             Chapter Overview 5.2.             Deep Learning in Diagnostics: Overall Market Landscape of Service / Technology Providers   6.                COMPANY PROFILES 6.2.             Aegicare 6.2.1.          Company Overview 6.2.2.          Service Portfolio 6.2.3.          Recent Developments and Future Outlook   6.3.             Aiforia Technologies 6.4.             Ardigen 6.5.             Berg 6.6.             Google 6.7.             Huawei 6.8.             Merative 6.9.             Nference 6.10.           Nvidia 6.11.           Owkin 6.12.           Phenomic AI 6.13.           Pixel AI   7.                PORTER’S FIVE FORCES ANALYSIS 7.1.             Chapter Overview 7.2.             Methodology and Assumptions 7.3.             Key Parameters 7.4.             Concluding Remarks   8.                CLINICAL TRIAL ANALYSIS 8.1.             Chapter Overview 8.2.             Scope and Methodology 8.3              Deep Learning Market: Clinical Trial Analysis   9.                FUNDING AND INVESTMENT ANALYSIS 9.1.             Chapter Overview 9.2.             Types of Funding 9.3.             Deep Learning Market: Funding and Investment Analysis   10.              START-UP HEALTH INDEXING 10.1.           Chapter Overview 10.2.           Start-ups Focused on Deep Learning in Drug Discovery 10.3.           Benchmarking Analysis of Start-ups Focused on Deep Learning in Drug Discovery 10.4.           Start-ups Focused on Deep Learning in Diagnostics 10.5.           Benchmarking Analysis of Start-ups Focused on Deep Learning in Diagnostics 10.5.1.        Analysis by Focus Area   11.              COMPANY VALUATION ANALYSIS 11.1.           Chapter Overview 11.2.           Company Valuation Analysis: Key Parameters 11.3.           Methodology 11.4.           Company Valuation Analysis: Roots Analysis Proprietary Scores   12.              MARKET SIZING AND OPPORTUNITY ANALYSIS: DEEP LEARNING IN DRUG DISCOVERY 12.1.           Chapter Overview 12.2.           Key Assumptions and Methodology 12.3.           Overall Deep Learning in Drug Discovery Market, 2023-2035   13.              MARKET SIZING AND OPPORTUNITY ANALYSIS: DEEP LEARNING IN DIAGNOSTICS 13.1.           Chapter Overview 13.2.           Key Assumptions and Methodology 13.3.           Overall Deep Learning in Diagnostics Market, 2023-2035   14.              DEEP LEARNING IN HEALTHCARE: EXPERT INSIGHTS   15.              CONCLUDING REMARKS   16.              INTERVIEW TRANSCRIPTS 16.1.           Chapter Overview 16.2.           Nucleai 16.3.           Mediwhale 16.4.           Arterys 16.5.           AlgoSurg 16.6.           ContextVision 16.7.           Advenio Technosys 16.8.           Arterys 16.9.           Arya.ai   17.              APPENDIX 1: TABULATED DATA   18.              APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS   To view more details on this report, click on the link https://www.rootsanalysis.com/reports/view_document/deep-learning-in-drug-discovery-market/156.html   You may also be interested in the following titles: Decentralized Clinical Trials / Virtual Clinical Trials Market  Exploring AI-based Digital Pathology Medical Device Coatings Market Roots Analysis Consulting - the preferred research partner for global firms   About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.   Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com    

The growing concern of patient non-compliance and poor adherence to conventional medication regimen has prompted various biopharmaceutical companies to leverage the expertise of players offering long-acting drug delivery technologies and services   Roots Analysis is pleased to announce the publication of its recent study, titled, “Long-Acting Drug Delivery Market, 2023-2035”   The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies. Amongst other elements, the report includes   An executive summary of the insights captured during our research. It offers a high-level view on the current state of long acting drugs delivery technologies and services market and its likely evolution in the mid-long term. A general overview of long-acting drug delivery and the different types of long-acting drug delivery systems. Additionally, it highlights the underlying principles and strategies associated with long-acting drug delivery. A detailed assessment of the current technology landscape of long-acting drug delivery technologies. A detailed assessment of the overall service providers landscape of the companies offering contract services related to long-acting drug delivery. A technology competitiveness analysis of long-acting drug delivery technologies. A company competitiveness analysis of long-acting drug delivery service providers. Elaborate profiles of prominent players developing technologies and offering services in the domain of long-acting drug delivery (shortlisted based on a proprietary criterion). A detailed analysis of the recent partnerships inked between stakeholders engaged in this domain, since 2018. A detailed analysis of over 570 peer-reviewed, scientific articles focused on research related to long-acting drug delivery. An in-depth analysis of various patents that have been filed / granted related to long-acting drug delivery, since 2018. A detailed review of academic grants that have been awarded to various research institutes for projects focused on long-acting drug delivery, since 2018. A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) Principle Manipulation of drug release from delivery systems Manipulation of in vivo clearance   Strategy Chemical Modification Micro-encapsulation Long-Acting Hydrogels Long-Acting Implants Long-Acting Microneedles Multivesicular Liposomes Nanocrystal Suspensions Protein Fusion   Compatible Dosage Form Injectables Implantables Oral Dosage Forms Topical / Transdermal Dosage Forms Vaginal Dosage Forms Other Dosage Forms   Type of Molecules Delivered Small Molecules Biologics Other Molecules   Type of Material Used Polymer based Non-polymer based   Key Geographical Regions North America Europe Asia-Pacific Middle East and North Africa   Key companies covered in the report Adare Pharma Solutions AMW Bostal Drug Delivery Creative Biolabs ForDoz Pharma Innocore Pharmaceuticals Integral BioSystems LATITUDE Pharmaceuticals Navin Saxena Research and Technology Centre (NSRT) Samyang Biopharm   To view more details on this report, click on the link https://www.rootsanalysis.com/reports/long-acting-drug-delivery-market.html   You may also be interested in the following titles: Oral Solid Dosage Manufacturing Market Lipid Nanoparticles in Drug Delivery Bioavailability enhancement services market Global Gene Switch Market             About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.   Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com  

The “Bispecific Antibodies Market report features an in-depth analysis, highlighting the pipeline of various players engaged in this domain.   Roots Analysis has announced the addition of “Bispecific Antibodies Market, 2023-2035” report to its list of offerings.   Key Inclusions A detailed review of the market landscape of over 220 bispecific antibodies that are either approved or being evaluated in different stages of clinical development, based on several relevant parameters, such as developer company, phase of development, target antigen, type of therapy, route of administration, method of administration, target indication, therapeutic area, disease segment, year of establishment, company size and location of headquarters of the developer. An in-depth assessment of the market landscape of over 180 bispecific antibodies that are currently being evaluated in preclinical studies, based on several relevant parameters, such as developer company, stage of development, target antigen, therapeutic area, disease segment, year of establishment, company size and location of headquarters of the developer. A detailed assessment of over 80 technology platforms being developed / used by various drug developers for the production of bispecific antibody therapeutics, featuring a 3-D comparative bubble analyses of bispecific antibody technology platforms based on multiple relevant parameters, such as clinical / preclinical pipeline strength, developer’s years of experience, company size and location of headquarters of developers. An in-depth analysis of big pharma players engaged in this domain, featuring insightful spider web analyses of such players, based on clinical stage competition, marketed drugs competition, clinical trial activity, partnership activity and technology portfolio strength. Additionally, it features heat map analyses, highlighting the comparison of big pharma players based on various relevant parameters, such as target antigen, antibody format, mechanism of action and target therapeutic area. Elaborate profiles of prominent drug developers engaged in the development of bispecific antibodies, featuring a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters, key members of the executive team, financial details / information (if available), drug portfolio, recent developments and an informed future outlook. An insightful analysis of various partnerships inked between stakeholders engaged within the bispecific antibody therapeutics domain, during the period 2016-2023, based on several relevant parameters, such as year of partnership, type of partnership, disease segment, type of payment model employed, deal amount, most active players (in terms of number of deals inked), most popular technologies (in terms of number of deals inked for technologies) and regional distribution of partnership activity. An in-depth analysis of ongoing and planned studies related to bispecific antibody therapeutics, which were registered till April 2023, taking into consideration several relevant parameters, such as trial registration year, trial phase, trial recruitment status, enrolled patient population, type of study, study design, type of sponsor / collaborator, leading industry and non-industry players, key focus areas and geographical location of trials. A review of different channels used for promoting marketed bispecific antibodies, along with examples of players that have undertaken such initiatives, elaborating on the various promotional strategies being adopted by developers of two approved bispecific antibodies (chosen based on their popularity in this domain), namely Blincyto™ and Hemlibra®, and comparison of both the drugs based on information available on their respective websites. A discussion on important, industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis highlighting the relative impact of each SWOT parameter on the overall market.   The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below: Therapeutic Area Autoimmune Disorders Genetic Disorders Hematological Malignancies Ophthalmic Disorders Skin Cancers Solid Tumors   Mechanism of Action Cytokines Retargeting / Neutralization Dual Ligands Blocking Resistance Factors Co-targeting Targeting Tumor Angiogenesis T-Cell Retargeting / Activation Others   Target Antigen C5-Albumin CD20 x CD3 CD3 x BCMA CD3 x CD19 EGFR x cMET EpCAM x CD3 Factor IXa x Factor X gp100 x CD3 HER2 x HER2 PD-1 x CTLA-4 PD-L1 x TGFβ TNF-α x HSA VEGF x DLL4 VEGF-A x ANG2   Antibody Format Asymmetric Fragments   Key Players Akeso Biopharma Alexion Amgen Genmab Immunocore Janssen Research & Development Linton Pharm Merck OncXerna Therapeutics Pfizer Roche Taisho Pharmaceutical Zymeworks   Key Geographical Regions Asia Europe North America Rest of the World   Key Questions Answered What is the overall size of the global bispecific antibody therapies market? What is the rate at which the bispecific antibodies market is likely to grow in the coming years? Which region has the highest growth rate in the bispecific antibodies market? Who are the leading players engaged in this market? How many players are engaged in developing bispecific antibodies? What are the most common antigens targeted by bispecific antibody therapeutics? Which target indication covers the largest share in bispecific antibody therapies market? What is the partnership and collaboration trend in the bispecific antibody therapeutics domain? What are the upcoming trends in bispecific antibody therapies market?     To view more details on this report, click on the link https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html   You may also be interested in the following titles: Medical Device Coatings and Surface Modification Technologies Market mRNA Synthesis and Manufacturing Services Market                      About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.   Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com  

The “Investor Series: Opportunities in Women’s Digital Health Market’’ report provides detailed information on the women’s digital health market, covering the core and peripheral women’s digital health solutions   Key Inclusions An executive summary of the insights captured during our research. It offers a high-level view on the current state of women’s digital health market and its likely evolution in the mid-long term along with the financial activity in this domain. An introduction to women’s digital health, highlighting some of the key application areas of the FemTech industry. It features various types of women’s digital health products / solutions that have either been marketed / are under development. In addition, the report highlights prominent barriers to the development and success of women’s digital health solutions, and the opinions of representatives from key stakeholder companies involved in this domain. A detailed analysis of women’s digital health focused companies that were established post-2006, featuring key insights on the observed trends related to the basic company parameters, such as year of establishment, location of headquarters, company size, and type of venture.  An assessment of the various products / solutions, offered by the innovator companies, featuring analysis based on number and types of products. Based on the aforementioned insights, we have developed a quantitative perspective on the relative health (based on the company details, product portfolio, financing activity, estimated revenues and profits) of the different innovator companies that have been described in detail in this report. This analysis is based on a proprietary scoring criterion, informed via secondary research. An informed perspective on the value proposition of the companies captured in the report based on multiple relevant aspects, namely product-related value, value to patients, developer value and outreach-related value. A company competitiveness analysis, which offers a quantitative basis for comparing the strengths / contributions of various industry stakeholders that are involved in providing women’s digital health solutions. It is worth mentioning that this analysis is based on the insights generated from the abovementioned relative health indexing and value proposition analysis. A detailed analysis of the women's digital health funding women's digital health investment activity that has taken place, since 2011. It also includes category-wise financing trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the innovator companies mentioned in the report. Further, it features a list of the leading investors in women’s digital health, based on their participation in financing activity in this industry segment. An elaborate review of the overall women’s digital health market from a financial perspective, including detailed fundamental (insights from the balance sheet and key financial ratios) and technical analysis (insights from historical and recent stock price variations as well as analysis using popular stock performance indicators) of financial data of the publicly listed companies within the innovators landscape dataset. A key acquisition targets analysis, based on the insights generated during the course of this study, highlighting some of the promising early-to-mid stage business ventures that are likely to be acquired / merged. A case study on the assessment of business risks, based on some of the major risk categories that are usually discussed in the industry, namely operations-related risks, business-related risks, financial / asset-related risks, product / technology risks, and others (social, economic, environmental and political risks). A case study where investors have exited various women’s digital health-related ventures, offering insights on return on investments received (based on availability of data). Leveraging the abovementioned details, the report offers an informed opinion on the future outlook for investors in the women’s digital health market.   The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:   Type of Solution Applications / Software Devices Services   Therapeutic Application Area Fetal Health General Wellness Menstrual Cycle Pelvic Care Reproductive Health / Fertility   Key Geographical Regions North America Europe Asia-Pacific Latin America Middle East and North Africa                                                                                          Key Questions Answered What are the key application areas of the FemTech industry? Who are the innovators offering women’s digital health solutions? What type of women’s digital health products / solutions are being offered by the innovator companies? What are the key value propositions offered by players engaged in the women’s digital health domain? What is the relative competitiveness of different players offering products / solutions focused on women’s health? Who are the key investors that are actively supporting the development and commercialization of women’s digital health products / solutions? What are the anticipated fundamental and technical trends of financial data of publicly listed companies within the innovator landscape? Who are the potential acquisition targets for investors in the women’s digital health sector? What are the major risks for investors seeking to tap into the women’s digital health domain? What is the estimated return on investments received by the investors? How is the current and future market opportunity related to women’s digital health likely to be distributed across key market segments?   Get more details on the report https://www.rootsanalysis.com/reports/opportunities-in-women-digital--health-market.html   You may also be interested in the following titles: Blockchain Technology in Healthcare Market  Autoinjectors   You may also like to learn what our experts are sharing in Roots educational series: Cell Therapy – The Revolutionary Therapeutic Modality: All Set To Obliterate Oncological Disorders 4D Bioprinting Market: Key Trends   About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.   Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com  

The new market report titled “Opportunities in the RNA Therapeutics Market”, published by Roots Analysis is one of the most sought-after solutions for investors operating in the RNA therapeutics market.   The report will help investors stay updated with the latest market trends and opportunities associated with the RNA therapeutics market. The report comes with a concise summary of the details regarding the historical market data, current market trends, future growth prospects, innovator and product landscape, company health indexing, value proposition analysis, company competitiveness, funding and investment, financial analysis of public ventures, business risk analysis, returns on investment and key acquisition targets, as well as the emerging market trends and opportunities in RNA therapeutics market. The opportunities in the RNA therapeutics market are anticipated to expand significantly.   However, the latest report is mainly intended for business leaders, experts, thought leaders, investors, start-ups and growth stage firms interested in RNA Therapeutics business space and is available in the form of PDF and spreadsheet.   Investor Series: Opportunities in the RNA Therapeutics Market: Investor Series Scope and Market Size: The report provides detailed information on the RNA therapeutics market, covering the core and peripheral RNA therapeutics solutions. It offers a technical and financial perspective on how the RNA therapeutics market opportunities is likely to evolve, in terms of future business success, over the coming decade. The RNA therapeutics market is broadly segmented on the basis of type of solution, type of therapy, therapeutic area and geographical regions. The segmental growth helps the investors, firms, business leaders to get a lucid picture of the niche pockets of growth, as well as the strategies deployed by the market players to drive the growth of these segments. This section of the report helps them understand and determine the core application areas and the differences between the target markets. The report scrutinizes the RNA therapeutics market in terms of market size & volume and significant information pertaining to product bifurcation and RNA therapeutics solutions overview.   Key Market Contenders: This particular section of the RNA therapeutics market report covers all the necessary details of the RNA therapeutics’ solutions developed by players operating in the RNA therapeutics market. The report goes on to elucidate a quantitative perspective on the relative health of the different innovator companies and an assessment of the various solutions, offered by the companies developing DTx solutions, featuring analysis based on number and types of products, and an informed perspective on the value of the offerings based on multiple relevant aspects.   Information on the funding and investment activity that has taken place in this domain since 2011 has also been included in this report. Moreover, the exhaustive report presents financing category-wise trends, describing the relative maturity of the innovator companies. Further, RNA therapeutics market features a list of the leading RNA therapeutics investors , based on their participation in financing activity in this industry segment. It also covers an elaborate review of the overall RNA therapeutics market from a financial perspective, including detailed fundamental (insights from the balance sheet, and key financial ratios) and technical analyses (insights from historical and recent stock price variations, and analysis using popular stock performance indicators) of financial data of the publicly listed companies.   This section of RNA therapeutics market report focusing on the competitive terrain of the RNA therapeutics market endows the reader with every significant detail and information about the leading competitors on the market. The report provides a key acquisition targets analysis, highlighting some of the promising early-to-mid stage business ventures around which there is likely to be interest for future acquisitions / mergers and also includes the case study of instances where investors have exited various RNA therapeutics related ventures, offering insights on return on investments made. Leveraging the abovementioned details, the report offers an informed opinion on the future outlook for investors in the RNA therapeutics market.   Section covered in RNA therapeutics market report: Section 01: Need for RNA Therapeutics and Innovators Landscape Section 02: Analysis of Investments Section 03: Financial Analysis and Assessment of Business Risks Section 04: Market Forecast and Opportunity Analysis Section 05: Analysis of Returns on Investment and Key Acquisition Targets   To view more details on this report, click on the link: https://www.rootsanalysis.com/reports/opportunities-in-RNA-therapeutics-market.html   You may also be interested in the following titles: Oral Solid Dosage Manufacturing Market Lipid Nanoparticles in Drug Delivery   You may also like to learn what our experts are sharing in Roots educational series: Cell Therapy – The Revolutionary Therapeutic Modality: All Set To Obliterate Oncological Disorders 4D Bioprinting Market: Key Trends   About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.                         Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com        

The new market report titled ‘CRISPR Technologies: Intellectual Property Landscape,’ published by Roots Analysis features an extensive study of some of the key historical and contemporary intellectual property (IP) documents (featuring granted patents, patent applications and other documents), describing the various types of CRISPR Technologies.   The insights generated in this report have been presented across two deliverables, namely a MS Excel workbook and a MS PowerPoint deck, summarizing the ongoing trend in this domain.   To view more details on this report, click on the link: https://www.rootsanalysis.com/reports/crispr-technologies-ip-landscape.html   Main Chapters in the CRISPR Technologies Intellectual Property Landscape Report   Overall Intellectual Property Landscape An analytical perspective of the various patents and affiliated IP documents that have been published related to CRISPR Technologies, since 2000. An in-depth analysis of published IP documents, representing unique patent families across various global jurisdictions, featuring insightful inferences related to both historical and recent R&D trends within this domain.   Popular / Relevant Prior Art Search Expressions An examination of IP literature, shortlisting key words and phrases used to describe CRISPR Technologies. The analysis also includes details on the historical use of the aforementioned terms across different IP filings, key affiliated terms and other related trends.   Patent Valuation Analysis Competitive benchmarking and valuation analysis of the key members of unique patent families captured in the report, taking into consideration important parameters of the patent application.   Patentability and Freedom to Operate A systematic and Roots Proprietary approach to identify relevant areas of innovation by analyzing published IP documents, by defining the uniqueness of patented / patent pending innovations, in order to assess the scope of patentability in this domain, and pinpoint jurisdictions wherein new and / or modified claims may be filed without infringing on existing IP.   Analysis of Patent Applications and Granted CRISPR Technologies Patents A detailed summary of the various patent applications and granted patents across different jurisdictions and their relative value in the IP ecosystem. The analysis classified the intellectual capital in terms of type of innovation and the innovation related to CRISPR Technologies, thereby offering the means to identify active arenas of research and assess innovation-specific IP filing trends.   Pockets of Innovation and White Spaces An insightful analysis of the various CPC codes used in published IP literature and their affiliated families, offering the means to identify historical and existing pockets of innovation, the analysis also features a discussion on prevalent white spaces.   Claim Analysis One of the objectives of the report was to analyze and summarize key inferences from the independent claims mentioned in granted, active patents in the dataset. Using a systematic segregation approach, we have analyzed trends associated with the preamble, type of patent, type of claim and other key elements of a claim.   Key Companies Profiled   10x Genomics 22nd Century Group 64x Bio Aadigen Aarhus University   You may also be interested in the following titles: Quantum Computing in Drug Discovery Services Market Viral Clearance and Viral Testing Services Market   You may also like to learn what our experts are sharing in Roots educational series: Is Blue Ocean Strategy The Silver Bullet For Emerging Teleradiology Players to Achieve A Breakthrough In This Highly Competitive Market?   Medical Device Coatings and Modification Technologies   About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.                         Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com            

Roots Analysis has announced the addition of “Modular Facilities in Pharmaceutical and Biotechnology Market (3rd Edition), 2023-2035” report to its list of offerings.   Key Market Insights Presently, over 50 modular facility providers are engaged in the healthcare market, located across the globe Currently, more than 250 modular cleanroom providers are offering controlled environments along with accessories in the healthcare domain The partnership activity for modular facilities in healthcare domain has grown at a CAGR of over 30%, in the past three years, 2018-2021 The projected future opportunity for companies engaged in this field is expected to be well distributed across size of facility, type of industry served, type of modular construct, type of construction component, purpose of facility, scale of operation, type of product, type of expansion, type of modular construction, type of material used and  key geographical regions. An insightful competitiveness analysis of players involved in the modular facilities manufacturing in the healthcare domain   Table of Contents   1.                     PREFACE 1.1.                  Introduction 1.2.                  Key Market Insights 1.3.                  Scope of the Report    1.4.                  Research Methodology 1.5.                  Frequently Asked Questions 1.6.                  Chapter Outlines   2.                     EXECUTIVE SUMMARY   3.                     INTRODUCTION 3.1.                  Chapter Overview 3.2.                  Historical Background 3.3.                  The Concept of Modular Facilities 3.3.1.               Types of Modular Constructs 3.3.2.               Modular Construction Process   3.4.                  Modular Construction in the Pharmaceutical Industry 3.4.1.               Advantages of Modular Construction in the Pharmaceutical Industry 3.4.2.               Modular Pharmaceutical Cleanrooms 3.4.2.1.                         Cleanroom Classifications and Current Standards 3.4.2.2.                         Regulations and Standards Concerning Modular Cleanroom Construction   3.5.                  Advantages of Modular Cleanrooms 3.6.                  Challenges and Future Prospects   4.                      MARKET LANDSCAPE: MODULAR FACILITY MANUFACTURERS 4.1.                  Chapter Overview 4.2.                  Modular Facility Manufacturers: Overall Market Landscape 4.2.1                Analysis by Year of Establishment 4.2.2.               Analysis by Company Size 4.2.3.               Analysis by Location of Headquarters 4.2.4.               Analysis by Year of Establishment and Location of Headquarters 4.2.5.               Analysis by Company Size and Location of Headquarters 4.2.6.               Analysis by Type of Industry Served 4.2.7.               Analysis by Geographical Coverage 4.2.8.               Analysis by Type of Industry Served and Geographical Coverage 4.2.9.               Analysis by GMP Compliance 4.2.10.             Analysis by Geographical Coverage and GMP Compliance 4.2.11.             Analysis by Type of Modular Construction 4.2.12.             Analysis by Type of Industry Served and Type of Modular Construction 4.2.13.             Analysis by Type of Material Used 4.2.14.             Analysis by Type of Modular Construction and Type of Material Used 4.2.15.             Analysis of Historical and Current Market Landscape Trends 4.2.15.1           Analysis by Company Size, Geographical Coverage and Type of Industry Served   5.                      MARKET LANDSCAPE: MODULAR CLEANROOM PROVIDERS 5.1.                  Chapter Overview 5.2.                  Modular Cleanroom Providers: Overall Landscape 5.2.1.               Analysis by Year of Establishment 5.2.2.               Analysis by Company Size 5.2.3.               Analysis by Location of Headquarters 5.2.4.               Analysis by Year of Establishment and Location of Headquarters 5.2.5.               Analysis by Company Size and Location of Headquarters 5.2.6.               Analysis by Type of Industry Served 5.2.7.               Analysis by Location of Headquarters and Type of Industry Served 5.2.8.               Analysis by Type of Modular Cleanroom Offered 5.2.9.               Analysis by Type of Industry Served and Type of Modular Cleanroom Offered 5.2.10.             Analysis by Type of Cleanroom Component Offered 5.2.11.             Analysis by Type of Industry Served and Cleanroom Component Offered 5.2.12.             Analysis by Type of Modular Cleanroom and Cleanroom Component Offered 5.2.13.             Analysis by Location of Headquarters, Type of Industry Served and Type of Modular Cleanroom Offered 5.2.14.             Analysis by Quality Certifications Obtained   6.                     MODULAR FACILITY MANUFACTURERS: COMPANY COMPETITIVENESS ANALYSIS 6.1                   Chapter Overview 6.2                   Assumptions / Key Parameters 6.3                   Methodology 6.4                     Company Competitiveness Analysis: Modular Facility Manufacturers 6.4.1.               Company Competitiveness Analysis: Benchmarking of Service Strength 6.4.2.               Company Competitiveness Analysis: Benchmarking of Partnership activity 6.4.3.                Company Competitiveness Analysis: Small Companies 6.4.4.                Company Competitiveness Analysis: Mid-Sized Companies 6.4.5.                Company Competitiveness Analysis: Large Companies   7.                      COMPANY PROFILES 7.1.                  Chapter Overview 7.2.                  Cytiva 7.2.1.               Company Overview 7.2.2.               Modular Facility-related Services 7.2.3.               Modular Projects 7.2.4.               Recent Developments and Future Outlook   7.3.                  G-Con Manufacturing 7.4.                  Germfree 7.5.                  IPM Technologies 7.6.                  KeyPlants 7.7.                  ModuleCo Pharma      7.8.                  NNE 7.9.                  Pharmadule   8.                      PARTNERSHIPS AND COLLABORATIONS 8.1.                  Chapter Overview 8.2.                  Partnership Models 8.3.                  Modular Facility Manufacturers: Partnerships and Collaborations 8.3.1.               Analysis by Year of Partnership 8.3.2.               Analysis by Type of Partnership 8.3.3.               Analysis by Year of Partnership and Type of Partnership 8.3.4.               Analysis by Type of Product 8.3.5.                Analysis by Type of Partnership and Type of Product 8.3.6.               Analysis by Type of Modular Facility 8.3.7.                Analysis by Type of Product and Type of Modular Facility 8.3.8.               Most Active Players: Analysis by Number of Partnerships 8.3.9.                Analysis by Location of Partner’s Headquarters 8.3.10.              Analysis by Location of Modular Facility 8.3.11.              Analysis by Type of Partnership and Location of Modular Facility 8.3.12.              Analysis by Type of Product and Location of Modular Facility 8.3.13.             Intercontinental and Intracontinental Partnerships 8.3.14.              Analysis by Country   9.                     CASE STUDY ON MODULAR PROJECTS IN PHARMACEUTICAL AND       BIOTECHNOLOGY INDUSTRY 9.1.                  Chapter Overview 9.2.                   Modular Facility Projects Undertaken in the Pharmaceutical and Biotechnology Industry 9.3.1.               Analysis by Type of Modular Facility 9.3.2.               Analysis by Size of Modular Facility 9.3.3.               Most Active Manufacturers: Analysis by Number of Projects Delivered 9.3.4.                Most Active Clients: Analysis by Number of Projects Received 9.3.5.                Analysis by Location of Modular Facility 9.3.6.               Analysis by Type of Facility and Size of Modular Facility 9.3.7.                Analysis by Client and Location of Facility   10.                    FACILITY CONSTRUCTION TRENDS IN THE PHARMACEUTICAL INDUSTRY 10.1.                Chapter Overview 10.2.                Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry: Historical Data for Top 20 Players 10.2.1.             Analysis by Number of Facilities Delivered 10.2.2.             Analysis by Type of Facility 10.2.3.             Analysis by Purpose of Facility 10.2.4.             Analysis by Type of Facility and Purpose of Facility 10.2.5.             Analysis by Type of Investment 10.2.6.             Analysis by Purpose of Facility and Type of Investment 10.2.7.             Analysis by Size of Facility 10.2.8.             Analysis by Type of Facility and Size of Facility 10.2.9.             Analysis by Purpose of Facility and Size of Facility 10.2.10.           Analysis by Location of Headquarters 10.2.11.           Analysis by Location of Facility 10.2.12.           Analysis by Type of Facility and Location of Facility   11.                    COST-TIME OPTIMIZATION FRAMEWORK 11.1.                Chapter Overview 11.2.                Key Assumptions and Methodology 11.3.                Factors Influencing Modular Construction 11.3.1.             Intrinsic Factors 11.3.2.             Extrinsic Factors 11.4.                Cost Efficiency Analysis 11.5.                Time-Benefit Analysis 11.6.                Concluding Remarks   12.                    MARKET FORECAST      12.1.                Chapter Overview 12.2.                Forecast Methodology and Key Assumptions 12.3.                Global Modular Facilities Market in the  Pharmaceutical / Biotechnology   Sector,                           2023-2035   12.4.                Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Size of Facility, 2023 and 2035 12.4.1.       Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for  Small Facilities, 2023-203 12.4.2.       Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Mid-sized Facilities, 2023-2035 12.4.3.       Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Large Facilities, 2023-2035 12.4.4.       Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Very Large Facilities, 2023-2035   12.5.          Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Type of Industry Served, 2023 and 2035 12.5.1.       Modular Facilities Market in the Pharmaceutical Industry, 2023-2035 12.5.2.       Modular Facilities Market in the Biotechnology Industry, 2023-2035   12.6.          Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Type of Modular Construct, 2023 and 2035 12.6.1.       Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Hybrid Skid Modular Constructs, 2023-2035 12.6.2.       Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Skid-Mounted Modular Constructs, 2023-2035 12.6.3.       Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Plug-and-Play Modular Constructs, 2023-2035 12.6.4.       Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Truckable Modular Constructs, 2023-2035 12.6.5.       Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Other Modular Constructs, 2023-2035   12.7.          Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Type of Construction Component, 2023 and 2035 12.7.1.       Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Process Equipment, 2023-2035 12.7.2.       Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Base Buildings, 2023-2035 12.7.3.       Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Mechanical, Electrical and Plumbing Systems, 2023-2035 12.7.4.       Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Process Commodities, 2023-2035 12.7.5.       Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Other Construction Components, 2023-2035   12.8           Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Purpose of Facility, 2023 and 2035 12.8.1.       Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Manufacturing, 2023-2035 12.8.2.       Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Aseptic Filling, 2023-2035 12.8.3.       Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Research and Development, 2023-2035 12.8.4.       Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Other Purposes, 2023-2035   12.9.          Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Scale of Operation, 2023 and 2035 12.9.1.       Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Clinical Scale, 2023-2035 12.9.2.             Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Commercial Scale, 2023-2035   12.10.              Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Type of Product, 2023 and 2035 12.10.1.           Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Cell and Gene Therapies, 2023-2035 12.10.2.           Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Vaccines, 2023-2035 12.10.3.           Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Biosimilars, 2023-2035 12.10.4.           Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Monoclonal Antibodies, 2023-2035 12.10.5.           Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Advanced Pharmaceuticals, 2023-2035 12.10.6.           Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Sterile Products, 2023-2035 12.10.7.           Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Viral Vectors, 2023-2035 12.10.8.           Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Other Products, 2023-2035   12.11.              Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Type of Facility, 2023 and 2035 12.11.1.           Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for New Facilities, 2023-2035 12.11.2.           Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Facility Expansions, 2023-2035 12.11.3.           Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Planned Expansions, 2023-2035   12.12.              Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Type of Modular Construction, 2023 and 2035 12.12.1.           Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Relocatable Modular Construction, 2023-2035 12.12.2.           Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Permanent Modular Construction, 2023-2035   12.13.              Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Type of Material Used, 2023 and 2035 12.13.1.           Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Steel, 2023-2035 12.13.2.           Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Wood, 2023-2035 12.13.3.           Modular Facilities Market in the Pharmaceutical / Biotechnology Sector for Concrete, 2023-2035   12.14.              Modular Facilities Market in the Pharmaceutical / Biotechnology Sector: Analysis by Geography, 2023 and 2035 12.14.1.           Modular Facilities Market in the Pharmaceutical / Biotechnology Sector in North America, 2023-2035 12.14.2.           Modular Facilities Market in the Pharmaceutical / Biotechnology Sector in Europe, 2023-2035 12.14.3.           Modular Facilities Market in the Pharmaceutical / Biotechnology Sector in Asia, 2023-2035 12.14.4.           Modular Facilities Market in the Pharmaceutical / Biotechnology Sector in Middle East and North Africa, 2023-2035  12.14.5.             Modular Facilities Market in the Pharmaceutical / Biotechnology Sector in Rest of the    World,                                2023-2035   12.15.                 Concluding Remaks   13.                        PREVALENT AND EMERGING INDUSTRY TRENDS 13.1.                   Chapter Overview 13.2.                   Adoption of Modular Facilities 13.3.                   Expansion of Existing Service Portfolio 13.4.                   Integration of Advanced Technologies 13.4.1.                Single-use Technologies 13.4.2.                Continuous Processing Technologies 13.4.3.                Other Advanced Technologies   14.                      FUTURE GROWTH OPPORTUNITIES 14.1.                   Chapter Overview 14.2.                   Visibility Amongst Start-Ups 14.3.                   Popularity Amongst Contract Manufacturing Organizations 14.4.                   Expansion of Existing Facilities 14.5.                   Adoption for Production of Biosimilars 14.6.                   Additional Opportunities 14.7.                   Key Growth Drivers for Modular Construction 14.8.                   Market Attractiveness in Emerging regions   15.                        CONCLUSION   16.                      EXECUTIVE INSIGHTS 16.1.                   Chapter Overview 16.2.                   Avon Modular 16.2.2.                Interview Transcript: Alan de Zayas (Modular Building Manufacturing and Construction      Team)   16.3.                   Environmental Systems Corporation 16.3.2.                Interview Transcript: Vernon Solomon (President)   16.4.                   Exyte 16.4.2.                Interview Transcript: François Abiven (Executive Vice President Global Business Unit BLS) and Luca Mussati (Vice President Technology and Innovation)   16.5.                   G-Con Manufacturing 16.5.2.                Interview Transcript: Maik Jornitz (Chief Executive Officer)   16.6.                   Modular Devices 16.6.2.                Interview Transcript: Mark Koers (Executive Vice President, Sales and Marketing)   16.7.                   ModWave 16.7.2.                  Interview Transcript: Pär Almhem (President)   16.8.                   Subzero Engineering 16.8.2.             Interview Transcript: Ward Patton (Director of Sales)   16.9.                Vernick 16.9.2.             Interview Transcript: Wes Temple (Director of Marketing)   16.10.              Zeton 16.10.2.             Interview Transcript: Sulogna Roy (Ex-Sales Manager)    17.                   APPENDIX I:  TABULATED DATA   18.                   APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS   To view more details on this report, click on the link https://www.rootsanalysis.com/reports/view_document/modular-manufacturing-market/178.html   You may also be interested in the following titles: Pharmaceutical Polymers / Medical Polymers Market Gene Switch Market    You may also like to learn what our experts are sharing in Roots educational series: Digital Therapies: The “Digital Pills” of current generation Medical Device Coatings and Modification Technologies                   About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.   Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

The latest research report titled ‘Deep Learning Market in Drug Discovery and Diagnostics Market’, published by Roots Analysis offers a comprehensive study of the Deep Learning Market in Drug Discovery and Diagnostics industry, while estimating the overall market size and the size and share of the key regional segments of the global market over historical period, as well as the projected timeline of 2023-2035.   The Deep Learning Market in Drug Discovery and Diagnostics market is expected to deliver robust growth over the forecast period, registering an impressive CAGR of 20%. The anticipated market growth is accredited to the significant surge in demand across the regional and global markets for the products and services offered by the Deep Learning Market in Drug Discovery and Diagnostics industry. The latest study provides readers with a granular analysis of the major developmental elements of the global market, potential business avenues, and the overall market dynamics. The report has been specially curated to offer a deep understanding of the competitive terrain of the global market, highlighting the leading market rivals, their market positions, product portfolios, gross revenue shares, profit margins, pricing analysis, sales network & distribution channels, and financial standing. Segmentation by Therapeutic Areas Oncological Disorders Oncological Disorders Neurological Disorders Neurological Disorders Endocrine Disorders Cardiovascular Disorders Respiratory Disorders Ophthalmic Disorders Musculoskeletal Disorders Inflammatory Disorders   Key Companies Profiled Aegicare Aiforia Technologies Ardigen Berg Google Huawei Merative Nference Nvidia Owkin Phenomic AI Pixel AI   Report also offer Complimentary Excel Data Packs Market Landscape Analysis (Drug Discovery) Market Landscape Analysis (Diagnostics) Clinical Trial Analysis Funding Analysis Start-up Health Indexing Company Valuation Analysis Market Sizing and Opportunity Analysis (Drug Discovery) Market Sizing and Opportunity Analysis (Diagnostics)   Report also includes EXPERT INSIGHTS by Sean Lane, Chief Executive Officer (Olive) Junaid Kalia, Founder NeuroCare and Adeel Memon, Assistant Professor, Neurology Specialist (West Virginia University Hospitals) David Reich, President (The Mount Sinai Hospital) and Robbie Freeman, Vice President of Clinical Innovation (The Mount Sinai Hospital) Elad Benjamin, Vice President, Business Leader Clinical Data Services (Philips) and Jonathan Laserson, Senior Deep Learning Researcher (Apple) Kevin Lyman, Founder and Chief Science Officer (Enlitic)   The latest research report specializes in the in-depth analysis of the macroeconomic and microeconomic factors affecting the Deep Learning in Drug Discovery and Diagnostics market development. The report also concentrates on the regulatory framework that is shaping the future of the global market. New and existing pricing structures, emerging application areas, and upcoming investment opportunities have also been detailed in the report. The report further studies the projected growth factors that are expected to influence the market dynamics over the forecast timeframe.   The study is inclusive of a comprehensive analysis of the commonly used marketing and promotional strategies adopted by the key market players. Taking into account the existing market development factors, historical events, and recent market trends, the study presents a balanced opinion on the future scenario of the Deep Learning Market in Drug Discovery and Diagnostics market. It thus supports its opinion by discussing the key corporate strategies, such as mergers & acquisitions, takeovers, joint ventures, and strategic alliances, used by the market players to strengthen their global footprint.   Research Methodology Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection.  The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the Deep Learning Market in Drug Discovery and Diagnostics market.   Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.    To view more details on this report, click on the link: https://www.rootsanalysis.com/reports/view_document/deep-learning-in-drug-discovery-market/156.html   You may also be interested in the following titles: mRNA Synthesis and Manufacturing Services Market Digital Twins Market   You may also like to learn what our experts are sharing in Roots educational series: Is Blue Ocean Strategy The Silver Bullet For Emerging Teleradiology Players to Achieve A Breakthrough In This Highly Competitive Market?   At-home Self-testing: A Giant Leap Towards Transformation in Diagnostic Sector   About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.  Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com        

Recent advancements in multiplexed profiling and tissue imaging methods have enabled the assessment of spatial heterogeneity in intact tissues; as a result, adoption of spatial omics solutions offering benefits over traditional methods, is increasing   Roots Analysis has announced the addition of “Spatial Genomics, Transcriptomics and Proteomics Solutions Market, 2022-2035” report to its list of offerings.   The Spatial Genomics Market report features an extensive study of the current market landscape and the likely future potential; associated with the spatial omics solutions market, over the next decade. The study also includes a detailed analysis of key drivers and trends within this evolving market. Amongst other elements, the report features: A detailed overview of the overall market landscape of spatial omics solutions based on several relevant parameters. A detailed overview of the overall market landscape of players engaged in offering spatial proteomics, transcriptomics and genomics solutions, based on year of establishment, company size, location of headquarters and regional landscape. A detailed competitiveness analysis of products based on parameters, such as supplier power and product specifications. Elaborate profiles of key players offering spatial omics solutions. An analysis of the various partnerships related to spatial omics solutions inked by players engaged in this domain. An in-depth analysis of patents related to spatial omics solutions, filed / granted, since 2003. A detailed review of around 600 peer-reviewed, scientific articles related to research on spatial omics solutions. An elaborate discussion on the various commercialization strategies that can be adopted by drug developers engaged in this domain, across different stages of therapy development, including prior to drug launch, at / during drug launch and post-marketing of the drug. A detailed review of the overall landscape of the live cell instruments market, highlighting the contributions of industry players, along with information on their year of establishment, company size, geographical location of headquarters, ownership and instruments specific parameters. A detailed review of the overall landscape of sequencing technologies market, highlighting the contributions of industry players, along with information on their year of establishment, company size, geographical location of headquarters, ownership and sequencers specific parameters. A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) Type of Solution Instruments Consumables Services   Sample Type DNA RNA Protein   Research Area Oncological Disorders Immunological Disorders Neurological Diorders Infectious Diseases Others   End User Pharmaceutical and Biotechnology Companies Academic and Research Institutes   Key Geographical Regions  North America Europe Asia-Pacific and Rest of the World   Key companies covered in the report 10x Genomics Akoya Biosciences Bruker Canopy Biosciences NanoString Technologies Vizgen Lunaphore Technologies Molecular Machines & Industries (MMI) Resolve Biosciences   To view more details on this report, click on the link https://www.rootsanalysis.com/reports/spatial-genomics-market.html   You may also be interested in the following titles: Cannabis Testing Market Decentralized Clinical Trials / Virtual Clinical Trials Market    You may also like to learn what our experts are sharing in Roots educational series: At-home Self-testing: A Giant Leap Towards Transformation in Diagnostic Sector SARM1: A Potential Therapeutic Target For Neurodegenerative Diseases                   About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.   Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com